Zhi Tong Cai Jing·2026-02-12 11:40Core Viewpoint - JPMorgan Chase increased its stake in Innovent Biologics (01801) by acquiring 585,900 shares at a price of approximately HKD 79.23 per share, totaling around HKD 46.42 million, resulting in a new holding of approximately 87.22 million shares, representing a 5.02% ownership stake [1] Group 1 - JPMorgan Chase's acquisition of 585,900 shares indicates a strategic investment in Innovent Biologics [1] - The purchase price of HKD 79.23 per share reflects the current market valuation of Innovent Biologics [1] - The total investment amount of HKD 46.42 million signifies JPMorgan's confidence in the company's future prospects [1] Group 2 - Following the acquisition, JPMorgan's total shareholding in Innovent Biologics reached approximately 87.22 million shares [1] - The updated ownership percentage of 5.02% positions JPMorgan as a significant stakeholder in Innovent Biologics [1]